SCN10A and myasthenia gravis: These results suggest that Nav1.8 can be targeted to reduce MG-evoked hyperalgesia; however, the 3 h time course of Nav1.8 action—reported by Huang et al. and Bierhaus et al.—is not sufficient to explain either the early-onset MG-evoked nociception (0–5 min) or the hyperalgesia (15–120 min) that we report here.